Your browser doesn't support javascript.
loading
Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein
Yeonsu Kim; Henning Jackobsen; Bettina Fuerholzner; Kathrin Eschke; Markus Hoffmann; Muhammad Zeeshan Chaudhry; Federico Bertoglio; Michael Hust; Marek Widera; Sandra Ciesek; Stefan Poehlmann; Luka Cicin-Sain.
Afiliación
  • Yeonsu Kim; Helmholtz Center for Infection Research
  • Henning Jackobsen; Helmholtz Center for Infection Research
  • Bettina Fuerholzner; Helmholtz Center for Infection Research
  • Kathrin Eschke; Helmholtz Center for Infection Research
  • Markus Hoffmann; German Primate Center - Leibniz Institute for Primate Research
  • Muhammad Zeeshan Chaudhry; Helmholtz Center for Infection Research
  • Federico Bertoglio; Technical University of Braunschweig
  • Michael Hust; Technical University of Braunschweig
  • Marek Widera; University Hospital, Goethe University Frankfurt am Main
  • Sandra Ciesek; Goethe Universtiy Frankfurt
  • Stefan Poehlmann; Deutsches Primatenzentrum GmbH - Leibniz-Institut fur Primatenforschung
  • Luka Cicin-Sain; Helmholtz-Zentrum fur Infektionsforschung GmbH
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-517953
ABSTRACT
Vaccines are central to controlling the coronavirus disease 2019 (COVID-19) pandemic but the durability of protection is limited for currently approved COVID-19 vaccines. Further, the emergence of variants of concern (VoCs) that evade immune recognition has reduced vaccine effectiveness, compounding the problem. Here, we show that a single dose of a murine cytomegalovirus (MCMV)-based vaccine, which expresses the spike (S) protein of the virus circulating early in the pandemic (MCMVS), protects highly susceptible K18-hACE2 mice from clinical symptoms and death upon challenge with a lethal dose of D614G SARS-CoV-2. Moreover, MCMVS vaccination controlled two immune-evading VoCs, the Beta (B.1.135) and the Omicron (BA.1) variants in BALB/c mice, and S-specific immunity was maintained for at least 5 months after immunization, where neutralizing titers against all tested VoCs were higher at 5-months than at 1-month post-vaccination. Thus, cytomegalovirus (CMV)-based vector vaccines might allow for long-term protection against COVID-19.
Licencia
cc_by_nc_nd
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Experimental_studies / Prognostic_studies Idioma: En Año: 2022 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Experimental_studies / Prognostic_studies Idioma: En Año: 2022 Tipo del documento: Preprint